Professor Sander van Deventer appointed to AMT supervisory board
pharmafile | May 10, 2010 | Appointment | Research and Development |Â Â AMT, Amsterdam Molecular Therapeutics, appointment, research and developmentÂ
Dutch human gene therapy company Amsterdam Molecular Therapeutics has appointed Professor Sander van Deventer to its supervisory board.
One of AMT’s co-founders, Professor van Deventer currently chairs its scientific advisory board and previously served as chief scientific officer until February 2009, and temporarily as chief executive Officer from February – October 2009.
He has over 15 years experience in biotechnology product development and serves as an advisor to regulatory authorities including the EMA and FDA.
The company has also appointed chief financial officer Piers Morgan to the management board, while Alexander Ribbink has retired as a member of the supervisory board.
Chief executive Jörn Aldag said: “AMT is delighted that Sander van Deventer is joining the supervisory board. His contributions to the continued development of the company have been, and will be, extremely valuable. We would also like to thank Alexander Ribbink for the support he has given to the Company during a period of significant progress and change for AMT.”
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






